ACHE and Alzheimer disease: Based on these new findings, the recent design of novel classes of AChE inhibitors as therapeutic intervention for AD has been shifted toward blocking the peripheral site of AChE, the Aβ recognition zone within the enzyme [9], thereby affect the AChE-induced Aβ aggregation and thus, modulate the progression of AD.